Iovance Biotherapeutics Inc (NASDAQ:IOVA) achieved the upper end of their 2024 revenue guidance, with total product revenue of $164.1 million. The company has a robust manufacturing network with a ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report). The company’s shares closed last Friday at ...

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.45 per share a year ago.

IOVA has been the subject of several other reports. Robert W. Baird dropped their target price on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating for the ...

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), with a price target of $22.00. The company’s shares closed ...

Shares of NASDAQ:IOVA opened at $4.04 on Monday. The firm has a market cap of $1.23 billion, a PE ratio of -2.71 and a beta of 0.53. The firm’s 50 day simple moving average is $6.21 and its 200 ...

Iovance Biotherapeutics, Inc. IOVA incurred a fourth-quarter 2024 loss of 26 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents. In the year-ago quarter, the company ...

Winter Storm Iliana was the second storm to hit the U.S. in one week, bringing snow and ice from parts of the Midwest to the Great Lakes and Northeast the week of February 10, 2025. Iliana came on ...

Iovance Biotherapeutics Inc (NASDAQ:IOVA) achieved the upper end of their 2024 revenue guidance, with total product revenue of $164.1 million. The company has a robust manufacturing network with a ...

The market expects Iovance Biotherapeutics (IOVA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...